Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VV 993

Next Previous
X
Search
Drug Profile

VV 993

Alternative Names: Anti-SARS-CoV-2 3CLpro inhibitor; JT-003 - Shanghai Junshi Biosciences; VV-993

Latest Information Update: 09 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Sciences; Shanghai Institute of Materia Medica
  • Developer Shanghai Junshi Biosciences; Vigonvita Life Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 01 Apr 2022 Pharmacodynamics and adverse events data from a preclinical study in COVID-2019 infections released by Shanghai Junshi Biosciences
  • 26 Jan 2022 Shanghai Junshi Biosciences partners with Vigonvita to jointly undertake the research, production and commercialization of VV 993 in the collaboration territory
  • 01 Jan 2022 Preclinical trials in COVID-2019 infections in China (PO) before January 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top